Recent patents concerning diagnostic and therapeutic applications of aberrantly methylated sequences in pancreatic cancer

Recent Patents on DNA and Gene Sequences

Volumn 2, Issue 2, 2008, Pages 97-106

  Wehrum, Diana ^a   Grützmann, Robert ^a   Hennig, Mario ^a   Saeger, Hans Detlev ^a   Pilarsky, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Aberrant DNA methylation; Cancer diagnostics; Cancer therapeutics; Pancreatic cancer; Patents

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPEPTIDE; CYTOSINE; DEPSIPEPTIDE; DINUCLEOTIDE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; FATTY ACID DERIVATIVE; GEMCITABINE; GENOMIC DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; PROTEIN HIN 1; RETINOID; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL SPECIFICITY; CONTINUOUS INFUSION; CPG ISLAND; DNA METHYLATION; DNA SYNTHESIS INHIBITION; EARLY CANCER; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; MARKER GENE; PANCREAS CANCER; PANCREAS CARCINOMA; PATENT; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; SCREENING TEST; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HUMANS; PANCREATIC NEOPLASMS; PATENTS AS TOPIC;

EID: 55849128917     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221508784534168     Document Type: Article

References (64)

1. Adler G, Seufferlein T, Bischoff SC, et al. Pankreaskarzinom: Kurzfassung der s3-leitlinie 2007. Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies. 2007: 1696-1700.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Smeenk HG, Tran TC, Erdmann J, et al. Survival after surgical management of pancreatic adenocarcinoma: Does curative and radical surgery truly exist? Langenbecks Arch Surg 2005; 390: 94-103.
4. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Onc 2007; 33: 266-70.
5. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-1839.
6. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160: 1573-1581.
7. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-3742.
8. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006; 13: 286-295.
9. Sato N, Fukushima N, Hruban RH, et al. Cpg island methylation profile of pancreatic intraepithelial neoplasia. Mol Psychiatry 2007.
10. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
11. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2 Suppl 1: S4-S11.
12. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 2005; 35: 293-301.
13. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: Basic concepts and clinical applications. Epigenetics 2006; 1: 7-13.
14. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
15. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
16. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005; 10: 631-647.
17. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a hela cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 1988; 2: 1136-43.
18. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007; 115: 1039-1059.
19. Baylin, S.B., Herman, J.: EP0954608 (2006).
20. Issa J-P. Cpg island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.
21. Brena RM, Costello JF. Genome-epigenome interactions in cancer. Hum Mol Genet 2007; 16: R96-R105.
22. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775: 138-162.
23. Herman JG, Jen J, Merlo A, et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15ink4b. Cancer Res 1996; 56: 722-727.
24. Issa JP. Cpg-island methylation in aging and cancer. Curr Top Microbiol Immunol 2000; 249: 101-118.
25. Anker P, Mulcahy H, Chen XQ, et al. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65-73.
26. Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mut Res 2007; 635: 105-117.
27. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids - a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007; 581: 795-799.
28. Lisitsyn NA, Segre JA, Kusumi K, et al. Direct isolation of polymorphic markers linked to a trait by genetically directed representational difference analysis. Nat Genet 1994; 6: 57-63.
29. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated cpg island amplification. Cancer Res 1999; 59: 2307-2312.
30. Dai S-M, Chen H-H, Chang C, et al. Ligation-mediated pcr for quantitative in vivo footprinting. Nat Biotech 2000; 18: 1108-11.
31. Rauch T, Pfeifer GP. Methylated-cpg island recovery assay: A new technique for the rapid detection of methylated-cpg islands in cancer. Lab Invest 2005; 85: 1172-1180.
32. Hughes S, Jones J. The use of multiple displacement amplified DNA as a control for methylation specific pcr, pyrosequencing, bisulfite sequencing and methylation-sensitive restriction enzyme pcr. BMC Mol Biol 2007; 8: 91.
33. Sulewska A, Niklinska W, Kozlowski M, et al. Detection of DNA methylation in eucaryotic cells. Folia Histochem Cytobiol 2007; 45: 315-24.
34. Hayatsu H, Negishi K, Shiraishi M, et al. Chemistry of bisulfite genomic sequencing; advances and issues. Nucleic Acids Symp 2007; 51: 47-8.
35. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci 1992; 89: 1827-1831.
36. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific pcr: A novel pcr assay for methylation status of cpg islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
37. Ronaghi M, UhlŽn M, NyrŽn aP. DNA sequencing: A sequencing method based on real-time pyrophosphate. Science 1998; 281: 363-365.
38. Ahmadian A, Ehn M, Hober S. Pyrosequencing: History, biochemistry and future. Clin Chim Acta 2006; 363: 83-94.
39. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Nucl Acids Res 2001; 29: e65-.
40. Shapiro R, Braverman B, Louis JB, et al. Nucleic acid reactivity and conformation. Ii. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem 1973; 248: 4060-4064.
41. Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. Bioorg Medic Chem Lett 2007; 17: 1912-1915.
42. Li, W., Li, J.M.: US20070141582 (2007).
43. Eads CA, Danenberg KD, Kawakami K, et al. Methylight: A high-throughput assay to measure DNA methylation. Nucl Acids Res 2000; 28: e32-.
44. Cottrell SE, Distler J, Goodman NS, et al. A real-time pcr assay for DNA-methylation using methylation-specific blockers. Nucl Acids Res 2004; 32: e10-.
45. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-149.
46. Sato N, Fukushima N, Matsubayashi H, et al. Identification of maspin and s100p as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2003; 23: 1531-1538.
47. Jacinto FV, Ballestar E, Ropero S, et al. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 2007; 67: 11481-6.
48. Model F, Osborn N, Ahlquist D, et al. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 2007; 5: 153-163.
49. Lofton-Day C, Model F, DeVos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54: 414-423.
50. Zhou D, Qiao W, Yang L, et al. Bisulfite-modified target DNA array for aberrant methylation analysis. Anal Biochem 2006; 351: 26-35.
51. DiMartino, J.F.: US20056905669 (2005).
52. Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 2007; 48: 1676-1695.
53. Ammerpohl O, Trauzold A, Schniewind B, et al. Complementary effects of hdac inhibitor 4-pb on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of pdac cells. Br J Cancer 2007; 96: 73-81.
54. Flynn J, Glickman JF, Reich NO. Murine DNA cytosine-c5 methyltransferase: Pre-steady- and steady-state kinetic analysis with regulatory DNA sequences. Biochemistry 1996; 35: 7308-7315.
55. Flynn J, Azzam R, Reich N. DNA binding discrimination of the murine DNA cytosine-c5 methyltransferase. J Mol Biol 1998; 279: 101-116.
56. Jones PA. Altering gene expression with 5-azacytidine. Cell 1985; 40: 485-486.
57. Ramchandani S, MacLeod AR, Pinard M, et al. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997; 94: 684-689.
58. Reich, N.O., Flynn, J.: US20067125857B2 (2006).
59. Goggins, M.G., Ueki, T.: US20067153656 (2006).
60. Polyak, K., Sgroi, D., Krop, I., Porter, D.: US20046815166 (2004).
61. Krop IE, Sgroi D, Porter DA, et al. Hin-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA 2001; 98: 9796-9801.
62. Krop I, Maguire P, Lahti-Domenici J, et al. Lack of hin-1 methylation in brca1-linked and "Brca1-like" Breast tumors. Cancer Res 2003; 63: 2024-2027.
63. Krop I, Player A, Tablante A, et al. Frequent hin-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004; 2: 489-494.
64. Krop I, Parker MT, Bloushtain-Qimron N, et al. Hin-1, an inhibitor of cell growth, invasion, and akt activation. Cancer Res 2005; 65: 9659-9669.